Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > Elliot, Ouch to the many haters could be a hate crime !
View:
Post by FarmerBetsy on Nov 22, 2023 10:53am

Elliot, Ouch to the many haters could be a hate crime !

An Embarrassment to say moving forward, the IND delayed by what 5-6 months, then delay another 6 months and start testing 8 healthy volunteers, no Alzheimers patients! I'm sure that's a first in phase 1 Alzheimers clinical trials.
The real story is not about Promis entering Alzheimer clinical trials that's not going to happen. More clear than ever. With the stock at or near all time history lows from $115. to $1.30/ share, Promis's focus has not been on creating company shareholder value, rather SELECTIVE shareholder value for a select Boston group, BOD's and MPT.  Issuing share placements through (PIPE'S) at these low pricies.
Shut down the TSX, Social media, a confusing website, outdated information can be pointed out in all kinds of directions hardly inviting for attracting investor interest.
The last PIPE with Institutional Investors all previous players like JP Morgan, Bank of America, Morgan Stanley, Royal Bank etc, all shut out in the (PIPE) .  Three new companies got to participate with Spera funds an Iraeli company getting 1.8 million shares. I wonder who made these connections Gail, Eugene, Elliot? Just another Promis demostration of SELECTIVITY in PP's
Comment by BottomBroker on Nov 22, 2023 3:59pm
https://www.roche.com/innovation/process/clinical-trials/about#b74e294d-1765-419e-8b38-96aaa88d62fa What are the different phases of a clinical trial? Clinical trials are categorized as Phase I to IV trials. They are generally described as follows: Phase I (small number of participants, normally between 6-10 healthy volunteers, or very sick patients for whom treatment ...more  
Comment by FarmerBetsy on Nov 22, 2023 4:37pm
For sure if you back Roche up 6-7 years ago with Gantenermab Phase 1, but look at the most recent trials not only Prothena and Acumen you won't just find 8 healthy patients. Prothena the latest filed an IND for an Alzheimers trial got it and the next month were recruiting.  Included are alzheimers patients which makes total sense. Bottombroker why don't you and Retired Cop who post ...more  
Comment by Alex1726 on Nov 23, 2023 6:56pm
The real story is not about Promis entering Alzheimer clinical trials that's not going to happen. I said that few years ago , they never intended to conduct any clinical trial , they just thought  they could surf on aducanumad's wave (and all others) and hoping to receive a takeover bid. They've waited as long as they could , but it never came.  They 've waited so long ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities